Added Warnings headers; Moved warnings below Relevance tier by entity section; Added some Overview headers to files missing them

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

<<Warn("The variants reported in this gene in BL failed QC")>>

Due to [minimal support](ACE#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

[[_TOC_]]

## Relevance tier by entity

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

| |2 |relevance in MCL not firmly established |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

[[_TOC_]]

## Relevance tier by entity

||1|high-confidence PMBL/cHL/GZL gene[@gomezUltraDeepSequencingReveals2023]|

| |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017;@drevalRevisitingReddyDLBCL2023; @arthurGenomewideDiscoverySomatic2018]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

## Overview

Due to [minimal support](ATP2C2#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

BRAF mutations, particularly the BRAF V600E hot spot mutation, are primarily associated with hairy cell leukemia and are rare in other B-cell lymphomas. These mutations play a crucial role in the pathogenesis of HCL and have important diagnostic and therapeutic implications. Although they are rare, mutations in BRAF are reproducibly observed in some DLBCLs. Another hot spot, D594A, occurs in DLBCL. The role of these in lymphomagenesis remains poorly understood but functional evidence suggests they may contribute to aneuploidy.[@tiacciBRAFMutationsHairycell2011]

Although mutations have also been reported in BL, due to [minimal support](BRAF#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

| |1 |high-confidence DLBCL gene [@tiacciBRAFMutationsHairycell2011]|

| |2 |Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_BRAF.md]]

Due to [minimal support](BRD4#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

BTG2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. Mutations in the BTG2 gene have been implicated in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), contributing to the development and progression of the disease. These mutations are a feature of the MCD genetic subgroup of DLBCL. The biological function of BTG2 mutations and their role in lymphomagenesis remains poorly understood. Due to [minimal support](BTG2#representative-mutations) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

| |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|

| |1 | aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_BTG2.md]]

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.¹ Subsequent exome and genome-wide studies of DLBCL did not reproduce this observation.

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Mutations in this gene were first described in BL in 2012 by Love et al¹ and subsequently in DLBCL by Reddy et al.² Subsequent exome and genome-wide studies of DLBCL and BL did not reproduce these observations.

| |2 |relevance in BL not firmly established [@loveGeneticLandscapeMutations2012]|

| |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.¹ Subsequent exome and genome-wide studies of DLBCL did not reproduce this observation.

|:------:|:----:|-----------------------------------------|

| |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

| |3 |Retired, Failed QC [@reddyGeneticFunctionalDrivers2017]|

| |1 |high-confidence BL gene [@grandeGenomewideDiscoverySomatic2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_CHD8.md]]

---

[[_TOC_]]

Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.¹ Subsequent exome and genome-wide studies of DLBCL did not reproduce this observation.

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

Due to [minimal support](CYP4F22#representative-mutation) in the original primary data, [low expression in BL](CYP4F22#cyp4f22-expression) and no mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.¹ Subsequent exome and genome-wide studies of DLBCL did not reproduce this observation.

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

Due to [minimal support](DLGAP1#representative-mutation) in the original primary data, [low expression in BL](DLGAP1#dlgap1-expression) and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |2 | Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Due to [minimal support](EML2#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

This gene has some recurrent sites of mutations (hot spots).

The mutation pattern in DLBCL implies the preferential accumulation of *inactivating mutations*.

| |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|

| |3 | Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_ETS1.md]]

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

Due to [minimal support](FGFR3#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

This is one of several genes that encode linker histone proteins that are recurrently mutated in DLBCL and FL.^1,2 Mutations are often found in the globular domain of the protein, which is critical for its interaction with DNA and other histone proteins.

## Relevance tier by entity

| |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

### DLBCL

---

[[_TOC_]]

| |2 |relevance in DLBCL not firmly established|

| |1 |high-confidence FL gene |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

This gene encodes the H2A protein, one of the core proteins comprising nucleosomes. Although relatively common in DLBCL, little is known about the function of these mutations.

| |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

### DLBCL

This gene encodes the H2A protein, one of the core proteins comprising nucleosomes. Although relatively common in DLBCL, little is known about the function of these mutations.

## Relevance tier by entity

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

| |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @chapuyMolecularSubtypesDiffuse2018]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

### DLBCL

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

||2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

||2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Overview

JUNB has been reported to be frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL).^{[@schuhmacherJUNBDUSP2SGK12019]} Mutations have also been reported in DLBCL but the mutation rate in the earliest study^{[@reddyGeneticFunctionalDrivers2017]} was likely an over-estimate.^{[@drevalRevisitingReddyDLBCL2023]} According to one study, mutations are often enriched at somatic hypermutation hotspot sites, indicating the involvement of aberrant somatic hypermutation in the pathogenesis of these lymphomas.^{[@schuhmacherJUNBDUSP2SGK12019]}

||2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|

| |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_JUNB.md]]

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

Due to [minimal support](KIFC3#representative-mutations) in the original primary data, [low expression in BL](KIFC3#kifc3-expression) and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

Although mutations in MTOR have been reported in DLBCL and some BL, their role in lymphomagenesis has not been thoroughly studied.

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

| |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017] |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_MTOR.md]]

---

[[_TOC_]]

## Relevance tier by entity

||2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|

| |3 |Retired, Failed QC|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

||2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

[[_TOC_]]

## Overview

The relevance of NOTCH1 mutations in various malignancies has been well established. However, *due to [minimal support](NOTCH1#representative-mutations) in the original primary data and very few mutations reported in subsequent BL studies, this gene is very unlikely to be relevant in BL.*

| |1 |high-confidence DLBCL gene |

| |1 |high-confidence MCL gene |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_NOTCH1.md]]

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

| |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 | Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

Due to [minimal support](PRSS22#representative-mutation) in the original primary data and very few mutations reported in subsequent studies, this gene is very unlikely to be relevant in BL.

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|--------------------------------------|

| |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]

## Relevance tier by entity

|:------:|:----:|-----------------------------------------|

| |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source |frequency (%)|

---

[[_TOC_]]